US-China Biomedical Technology, Inc. (UCBB) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
2 PARK PLAZA, SUITE 400 IRVINE, CA 92614 |
| State of Incorp. | NV |
| Fiscal Year End | February 28 |
| Industry (SIC) | 7311 - Advertising Agencies (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 5/31/2019 MRQ | 2/28/2019 | 2/28/2018 | 2/28/2017 | 2/29/2016 | 2/28/2015 | 2/28/2014 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 36,542 | 56,407 | 3,366 | 2,680 | 22 | 22 | |||
| Cash and cash equivalent | 36,542 | 56,407 | 3,366 | 2,680 | 22 | 22 | |||
| Receivables | 57,037 | ||||||||
| Prepaid expense | 21,726 | 5,000 | 2,500 | 175 | |||||
| Deposits current assets | 175 | 175 | 175 | 175 | |||||
| Total current assets: | 58,268 | 61,407 | 6,041 | 2,855 | 57,409 | 197 | |||
| Noncurrent Assets | |||||||||
| Deposits noncurrent assets | 19,219 | 19,219 | |||||||
| Total noncurrent assets: | 19,219 | 19,219 | |||||||
| Other undisclosed assets | (175) | ||||||||
| TOTAL ASSETS: | 77,487 | 80,626 | 6,041 | 2,855 | 57,234 | 197 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 27,811 | 45,959 | 14,151 | 30,666 | 88,084 | 99,566 | |||
| Employee-related liabilities | 6,216 | 27,806 | 58,650 | ||||||
| Accounts payable | 21,595 | 18,153 | 14,151 | 30,666 | 29,434 | 78,916 | |||
| Accounts payable and other accrued liabilities | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 20,650 | ||
| Debt | 45,000 | ||||||||
| Deferred rent credit | 8,167 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Due to related parties | 1,600 | 261,474 | 51,000 | ||||||
| Total current liabilities: | 37,578 | 352,433 | 14,151 | 30,666 | 88,084 | 150,566 | |||
| Noncurrent Liabilities | |||||||||
| Other undisclosed liabilities | 38,500 | ||||||||
| Total liabilities: | 76,078 | 352,433 | 14,151 | 30,666 | 88,084 | 150,566 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 1,409 | (271,807) | (8,110) | (27,811) | (30,850) | (150,369) | |||
| Common stock | 15,510 | 13,510 | 13,027 | 13,027 | 13,027 | 99,858 | |||
| Additional paid in capital | 2,922,682 | 1,940,526 | 1,722,542 | 1,658,042 | 1,598,034 | 1,171,453 | |||
| Accumulated deficit | (2,936,783) | (2,225,843) | (1,743,679) | (1,698,880) | (1,641,911) | ||||
| Other undisclosed equity, attributable to parent | (1,421,680) | ||||||||
| Total equity: | 1,409 | (271,807) | (8,110) | (27,811) | (30,850) | (150,369) | |||
| TOTAL LIABILITIES AND EQUITY: | 77,487 | 80,626 | 6,041 | 2,855 | 57,234 | 197 | |||
Income Statement (P&L) (USD)
| 5/31/2019 TTM | 2/28/2019 | 2/28/2018 | 2/28/2017 | 2/29/2016 | 2/28/2015 | 2/28/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (522,059) | (515,522) | (43,999) | (56,169) | (218,944) | (342,257) | ||
| Other operating income, net (Other Expenses) | 174,190 | |||||||
| Other undisclosed operating loss | (676,794) | |||||||
| Operating loss: | (522,059) | (515,522) | (43,999) | (56,169) | (218,944) | (844,861) | ||
| Nonoperating expense (Other Nonoperating expense) | (188,081) | |||||||
| Interest and debt expense | (3,925) | 34,263 | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (714,065) | (481,259) | (43,999) | (56,169) | (218,944) | (844,861) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 3,925 | 1 | (174,190) | |||||
| Loss from continuing operations before income taxes: | (710,140) | (481,258) | (43,999) | (56,169) | (218,944) | (1,019,051) | ||
| Income tax expense | (800) | (906) | (800) | (800) | (1,287) | (818) | ||
| Loss from continuing operations: | (710,940) | (482,164) | (44,799) | (56,969) | (220,231) | (1,019,869) | ||
| Loss before gain (loss) on sale of properties: | (710,940) | (482,164) | (44,799) | (56,969) | (220,231) | (1,019,869) | ||
| Net loss available to common stockholders, diluted: | (710,940) | (482,164) | (44,799) | (56,969) | (220,231) | (1,019,869) | ||
Comprehensive Income (USD)
| 5/31/2019 TTM | 2/28/2019 | 2/28/2018 | 2/28/2017 | 2/29/2016 | 2/28/2015 | 2/28/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (710,940) | (482,164) | (44,799) | (56,969) | (220,231) | (1,019,869) | ||
| Comprehensive loss, net of tax, attributable to parent: | (710,940) | (482,164) | (44,799) | (56,969) | (220,231) | (1,019,869) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.